VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

VJVirtual | Management of Irish ALK+ NSCLC patients with brigatinib

Jarushka Naidoo • 4 Nov 2020
Lung Cancer Non-Small Cell Lung Cancer Brigatinib Crizotinib
ALTA-1L

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, discusses the impact of the changes of brigatinib reimbursement in Irish patients with ALK+ non-small cell cancer (NSCLC), based on the results of the Phase III ALTA-1L study (NCT02737501). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

More from Jarushka Naidoo

4:32
Key NSCLC updates
Jarushka Naidoo • 4 Nov 2020
1:12
Exciting updates at the Gathering around Cancer meeting
Jarushka Naidoo • 4 Nov 2020
0:55
Osimertinib for EGFR-mutant lung cancer
Jarushka Naidoo • 4 Nov 2020

Related Videos

1:40
IASC WCLC 2021: CX-2029 and AMG 757 for lung cancer
Melissa Johnson • 8 Jan 2021
2:38
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
Melissa Johnson • 8 Jan 2021
2:57
NGS key for optimal lung cancer treatment
Melissa Johnson • 8 Jan 2021
1:29
Updates from the Sarah Cannon Research Institute
Melissa Johnson • 8 Jan 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals